
Heart Rate : 98 bpm / Tested On : 31-Oct-23 09:03:29 / HF 0.05 Hz - LF 100 Hz / Notch 50 Hz / Sn 1.00 Cm/mV / Sw 25 mm/s / Refd By:: ACROFEMI HEALTH

ECG







3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

AGE & SEX: 58Y/M
DATE: 05/11/2023

USG: WHOLE ABDOMEN (Male)

LIVER

: Is normal in size, shape and echogenecity.

The IHBR and hepatic radicals are not dilated. No evidence of focal echopoor/echorich lesion seen.

Portal vein diameter and common bile duct appear normal.

GALL

: Is normal in size, shape and echotexture. Walls are smooth and

BLADDER regular with normal thickness. There is no evidence of cholelithiasis.

PANCREAS: Is normal in size, shape and echotexture. Pancreatic duct is not dilated.

: Is normal in size shape and echogenecity Spleenic hilum is not dilated.

KIDNEYS: Bilateral Kidneys are normal in size, shape and echotexture,

corticomedullary differentiation is fair and ratio appears normal.

Pelvi calyceal system is normal. No evidence of hydronephrosis/ nephrolithiasis.

URINARY: Bladder walls are smooth, regular and normal thickness.

BLADDER: No evidence of mass or stone in bladder lumen.

PROSTATE: Is normal in size, shape and echotexture.

measures: 40 x 32 x 29 mm, wt: 20 gms.

Its capsule is intact and no evidence of focal lesion.

SPECIFIC: No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.

: NO evidence of lymphadenopathy or mass lesion in retroperitoneum.

: Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION:- NORMAL STUDY

DR NEERA MEHTA MBBS, DMRD RMCNO.005807/14853



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com CIN NO.: U85195RJ2004PTC019563

PATIENT: MR. VEER SINGH JATAV

AGE / SEX: 58Y/MALE

REF. BY: MEDIWHEEL

DATE: 31.10.2023

REPORT: DIGITAL X-RAY CHEST PA VIEW

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle is clear.

Domes of diaphragm are normally placed.

Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBIVIOUS ABNORMALITY DETECTED.

DR NEERA MEHTA MBBS, DMRD



20/84 8400

Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

NAME	MR VEER SINGH JATAV	AGE	58Y	SEX	MALE
REF BY	MEDI WHEEL	DATE	31/10/2023	REG NO	
	ECHOCADI	TICLE TO A RAP PAR			
WINDO	N- POOR/ADEQUATE/GOODVALV	OIOGRAM RE	PORT		
WINDOV MITRAL			ALICENSIA PRODUCTION	NORMA	<u> </u>

2D/1VI-1VIOD						
IVSD mm	8.5	IVSS mm	12.9	AORTA mm	26.4	
LVID mm	40.9	LVIS mm	26.7	LA mm	28.1	-
LVPWD mm	8.8	LVPWS mm	12.9	EF%	60%	
			THE STATE OF THE S		100-100-100-100-100-100-100-100-100-100	

CHAIVIBERS	11			
LA	NORMAL	RA	NORMAL	
LV	NORMAL	RV	NORMAL	
PERICARDILIM	NORMAL			

DOPPLER STUDY MITRAL			
PEAK VELOCITY m/s E/A	0.77/1.28	PEAK GRADIANT MmHg	Y
MEAN VELOCITY m/s	and the little	MEAN GRADIANT MmHg	
MVA cm2 (PLANITMETERY)		MVA cm2 (PHT)	
MAD			

MR		The second secon	
AORTIC			
PEAK VELOCITY m/s	1.42	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	

TEAK VELOCITI III/3	1.42	FEAR GRADIANT WITTING	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
AR			
TRICUSPID	A		-
PEAK VELOCITY m/s	0.46	PEAK GRADIANT MmHg	

DITIMONARY	White the state of	Man wife Marrie Marrie Married	
TR		PASP mmHg	
MEAN VELOCITY m/s	, MAC	MEAN GRADIANT MmHg	
PEAK VELOCITY m/s	0.46	PEAK GRADIANT MmHg	

POLIVIONARY			
PEAK VELOCITY m/s	0.95	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s	**	MEAN GRADIANT MmHg	_
PR		RVEDP mmHg	

IMPRESSION

- LV DIASTOLIC DYSFUNCTION GRADE-1
- NORMAL LV SYSTOLIC FUNCTION
- NO RWMA LVEF 60%
- NORMAL RV FUNCTION
- NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL


CONCLUSION: DIASTOLIC DYSFUNCTION, FAIR LV FUNCTION.



AAKRITI LABS PVT.LTD JAIPUR
68853 / MR. VEER SINGH JATAV / 58 Yrs / M/ Non Smoker
Heart Rate : 98 bpm / Tested On : 31-Oct-23 09:03:29 / HF 0.05 Hz - LF 100 Hz / Notch 50 Hz / Sn 1.00 Cm/mV / Sw 25 mm/s
/ Refd By.: ACROFEMI HEALTH

ECG







PATIENT NAME: VEER SINGH JATAV

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001893 PATIENT ID : VEERM211065251 CLIENT PATIENT ID: 012310210052

ABHA NO

AGE/SEX :58 Years Male DRAWN :21/10/2023 13:02:00 RECEIVED: 21/10/2023 13:17:58

REPORTED :05/11/2023 15:20:38

Test Report Status Results **Final Biological Reference Interval** Units

<u></u>							
HAEMATOLOGY - CBC							
MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE							
BLOOD COUNTS,EDTA WHOLE BLOOD							
HEMOGLOBIN (HB)	13.5	13.0 - 17.0	g/dL				
METHOD: CYANIDE FREE DETERMINATION							
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.63	4.5 - 5.5	mil/μL				
WHITE BLOOD CELL (WBC) COUNT	6.80	4.0 - 10.0	thou/µL				
METHOD : ELECTRICAL IMPEDANCE			, ,				
PLATELET COUNT	74 Low	150 - 410	thou/µL				
METHOD: ELECTRONIC IMPEDANCE							
RBC AND PLATELET INDICES							
HEMATOCRIT (PCV)	40.8	40 - 50	%				
METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR VOLUME (MCV)	88.0	83 - 101	fL				
METHOD : CALCULATED PARAMETER	00.0	05 101	· <u>-</u>				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	29.1	27.0 - 32.0	pg				
METHOD : CALCULATED PARAMETER	22.0	24 5 24 5	a /dl				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	33.0	31.5 - 34.5	g/dL				
METHOD : CALCULATED PARAMETER							
RED CELL DISTRIBUTION WIDTH (RDW)	13.8	11.6 - 14.0	%				
METHOD : CALCULATED PARAMETER MENTZER INDEX	19.0						
MEAN PLATELET VOLUME (MPV)	19.0 11.3 High	6.8 - 10.9	fL				
METHOD : CALCULATED PARAMETER	II.3 High	0.8 - 10.9	IL.				
TETTOS. G. LEGGE (IES 17 WO WIE LEIK							
WBC DIFFERENTIAL COUNT							
NEUTROPHILS	61	40 - 80	%				
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	01	→ 0 00	70				
LYMPHOCYTES	34	20 - 40	%				
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	04	2 10	%				
MONOCYTES	04	2 - 10	%0				



Consultant Pathologist





Page 1 Of 18









PATIENT NAME: VEER SINGH JATAV

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001893

PATIENT ID : VEERM211065251 CLIENT PATIENT ID: 012310210052

ABHA NO

AGE/SEX :58 Years Male DRAWN :21/10/2023 13:02:00 RECEIVED: 21/10/2023 13:17:58 REPORTED :05/11/2023 15:20:38

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
EOSINOPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	01	1 - 6	%
BASOPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	00	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED PARAMETER	4.15	2.0 - 7.0	thou/μL
ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED PARAMETER	2.31	1.0 - 3.0	thou/μL
ABSOLUTE MONOCYTE COUNT METHOD: CALCULATED PARAMETER	0.27	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD: CALCULATED PARAMETER	0.07	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.8		

Sh>Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

RBC AND PLAILLET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13 from Beta thalassaemia trait
(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 10.55.04

106504


This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain **Consultant Pathologist** Page 2 Of 18













PATIENT NAME: VEER SINGH JATAV

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030

8800465156

ACCESSION NO : 0251WJ001893

PATIENT ID : VEERM211065251
CLIENT PATIENT ID: 012310210052

ABHA NO :

AGE/SEX : 58 Years Male
DRAWN :21/10/2023 13:02:00

RECEIVED : 21/10/2023 13:17:58 REPORTED :05/11/2023 15:20:38

%

Test Report Status Final Results Biological Reference Interval Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

BLOOD 7.3 High

Non-diabetic: < 5.7
Pre-diabetics: 5.7 - 6.4
Diabetics: > or = 6.5
Therapeutic goals: < 7.0
Action suggested: > 8.0

(ADA Guideline 2021)

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) **162.8 High** < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

Dr. Akansha Jain Consultant Pathologist



Page 3 Of 18

View Details

View Report





PATIENT NAME: VEER SINGH JATAV

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

REF. DOCTOR: SELF ACCESSION NO: 0251WJ001893

PATIENT ID : VFFRM211065251 CLIENT PATIENT ID: 012310210052

ABHA NO

AGE/SEX :58 Years Male :21/10/2023 13:02:00 DRAWN

RECEIVED: 21/10/2023 13:17:58 REPORTED :05/11/2023 15:20:38

Test Report Status Final Results **Biological Reference Interval** Units

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

mm at 1 hr E.S.R 0 - 14

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

Interpretation(s)
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for wellcontrolled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

- anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

<b

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease

(Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

<br

-

 salicylates)

REFERENCE:
1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Akansha Jain **Consultant Pathologist**





Page 4 Of 18

PERFORMED AT:



PATIENT NAME: VEER SINGH JATAV

REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

PATIENT ID : VEERM211065251 CLIENT PATIENT ID: 012310210052

ACCESSION NO: 0251WJ001893

AGE/SEX :58 Years Male DRAWN :21/10/2023 13:02:00 RECEIVED: 21/10/2023 13:17:58

WEST DELHI **NEW DELHI 110030** 8800465156

ABHA NO

REPORTED :05/11/2023 15:20:38

Test Report Status Final Results **Biological Reference Interval** Units

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE B

METHOD: TUBE AGGLUTINATION

RH TYPE **POSITIVE**

METHOD: TUBE AGGLUTINATION

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.'

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain **Consultant Pathologist** Page 5 Of 18











PATIENT NAME: VEER SINGH JATAV

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: **0251WJ001893**PATIENT ID: VEERM211065251

CLIENT PAπENT ID: 012310210052

ABHA NO

AGE/SEX :58 Years Male DRAWN :21/10/2023 13:02:00 RECEIVED :21/10/2023 13:17:58

REPORTED :05/11/2023 15:20:38

Test Report Status <u>Final</u> Results Biological Reference Interval Units

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 148 High 74 - 99 mg/dL

METHOD: GLUCOSE OXIDASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) **207 High** 70 - 140 mg/dL

METHOD: GLUCOSE OXIDASE

METHOD: CHOLESTEROL OXIDASE

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL 125 < 200 Desirable mg/dL

200 - 239 Borderline High

>/= 240 High

TRIGLYCERIDES 143 < 150 Normal mg/dL

150 - 199 Borderline High

200 - 499 High >/=500 Very High

METHOD: LIPASE/GPO-PAP NO CORRECTION

METHOD: DIRECT CLEARANCE METHOD

HDL CHOLESTEROL 47 < 40 Low mg/dL

>/=60 High

CHOLESTEROL LDL 50 < 100 Optimal mg/dL

100 - 129

Near optimal/ above optimal

130 - 159

Borderline High

160 - 189 High >/= 190 Very High

NON HDL CHOLESTEROL 78 Desirable: Less than 130 mg/dL

Above Desirable: 130 - 159 Borderline High: 160 - 189

Hiah: 190 - 219

Very high: > or = 220

METHOD: CALCULATED PARAMETER

Dr. Akansha Jain Consultant Pathologist



Page 6 Of 18

View Details

View Repor







PATIENT NAME: VEER SINGH JATAV	REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030

8800465156

ACCESSION NO : **0251WJ001893**PATIENT ID : VEERM211065251

CLIENT PATIENT ID: 012310210052 ABHA NO :

05251 PI

AGE/SEX :58 Years Male
DRAWN :21/10/2023 13:02:00
RECEIVED :21/10/2023 13:17:58
REPORTED :05/11/2023 15:20:38

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
VERY LOW DENSITY LIPOPROTEIN	28.6	= 30.0 mg/dL</td
CHOL/HDL RATIO	2.7 Low	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk
LDL/HDL RATIO	1.1	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk g	roup or recurrent ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 r	najor risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	a	
High Risk	1. Three major ASCVD risk factors. 2. Dia	betes with 1 major risk factor or no evidence of end organ	
	damage. 3. CKD stage 3B or 4. 4. LDL >1	90 mg/dl 5. Extreme of a single risk factor. 6. Coronary	
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	ctors	
1 Age > or = 45 years in males and > or = 55 years in females 3 Current Cigarette smoking or tobacco use			
2. Family history of p	2. Family history of premature ASCVD 4. High blood pressure		
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug T	herapy
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	<OR = 60)		

Dr. Akansha Jain Consultant Pathologist



Page 7 Of 18

View Details









MC-5726

REF. DOCTOR: SELF

PATIENT NAME: VEER SINGH JATAV

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO : 0251WJ001893

PATIENT ID: VEERM211065251

ABHA NO :

AGE/SEX : 58 Years Male
DRAWN :21/10/2023 13:02:00
RECEIVED :21/10/2023 13:17:58

REPORTED :05/11/2023 15:20:38

Test Report Status Final

Results

Biological Reference Interval Units

Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.88	0 - 1	mg/dL
METHOD: DIAZO WITH SULPHANILIC ACID	0.07 11:-1	0.00	/ all
BILIRUBIN, DIRECT	0.27 High	0.00 - 0.25	mg/dL
METHOD: DIAZO WITH SULPHANILIC ACID	0.61	0.1 1.0	ma/dl
BILIRUBIN, INDIRECT	0.61	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER TOTAL PROTEIN	7.8	6.4 - 8.2	g/dL
METHOD: BIURET REACTION, END POINT	7.8	0.4 - 8.2	9, 42
ALBUMIN	4.6 High	3.8 - 4.4	g/dL
METHOD: BROMOCRESOL GREEN	-		<u>.</u>
GLOBULIN	3.2	2.0 - 4.1	g/dL
METHOD: CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.4	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE	37	0 - 37	U/L
(AST/SGOT)			
METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C	70	0 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C	38	0 - 40	0/ L
ALKALINE PHOSPHATASE	81	39 - 117	U/L
METHOD: AMP OPTIMISED TO IFCC 37° C	01	33 117	0, 2
GAMMA GLUTAMYL TRANSFERASE (GGT)	103 High	11 - 50	U/L
METHOD: GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC) 3	_	-	•
LACTATE DEHYDROGENASE	325	230 - 460	U/L

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN 8 5.0 - 18.0 mg/dL

METHOD: UREASE KINETIC

Dr. Akansha Jain Consultant Pathologist



Page 8 Of 18

View Details









PATIENT NAME: VEER SINGH JATAV

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO : **0251WJ001893**PATIENT ID : VEERM211065251

CLIENT PATIENT ID: 012310210052

ABHA NO :

AGE/SEX :58 Years Male
DRAWN :21/10/2023 13:02:00
RECEIVED :21/10/2023 13:17:58
REPORTED :05/11/2023 15:20:38

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CREATININE, SERUM

CREATININE 0.83 0.8 - 1.3 mg/dL

METHOD: ALKALINE PICRATE NO DEPROTEINIZATION

BUN/CREAT RATIO

BUN/CREAT RATIO 9.64

METHOD: CALCULATED PARAMETER

URIC ACID, SERUM

URIC ACID 6.2 3.4 - 7.0 mg/dL

METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE

TOTAL PROTEIN, SERUM

TOTAL PROTEIN 7.8 6.4 - 8.3 g/dL

METHOD: BIURET REACTION, END POINT

ALBUMIN, SERUM

ALBUMIN **4.6 High** 3.8 - 4.4 g/dL

METHOD: BROMOCRESOL GREEN

GLOBULIN

GLOBULIN 3.2 2.0 - 4.1 g/dL

ELECTROLYTES (NA/K/CL), SERUM

Dr. Akansha Jain Consultant Pathologist





Page 9 Of 18

View Details

View Report







PATIENT NAME: VEER SINGH JATAV

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO : 0251WJ001893 PATIENT ID : VEERM211065251

CLIENT PATIENT ID: 012310210052

ABHA NO

AGE/SEX :58 Years Male DRAWN :21/10/2023 13:02:00 RECEIVED: 21/10/2023 13:17:58

REPORTED :05/11/2023 15:20:38

Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
SODIUM, SERUM METHOD: ION-SELECTIVE ELECTRODE	139.9	137 - 145	mmol/L
POTASSIUM, SERUM	3.95	3.6 - 5.0	mmol/L
METHOD: ION-SELECTIVE ELECTRODE CHLORIDE, SERUM METHOD: ION-SELECTIVE ELECTRODE	102.9	98 - 107	mmol/L

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chron c respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular flu d volume, adrenalinsufficiency, hyperaldosterorism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Normally, the glucose concentration in extracential indices access, regulated by a concentration of extracential indices access, regulated by a concentration of extracential indices access, regulated by a concentration of the urine.

Ab>Increased in
(b) Pancreatic islet cell disease with increased insulin,insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g. galactosemia), Drugsinsulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

<

Dr. Akansha Jain **Consultant Pathologist**



Page 10 Of 18







PATIENT NAME: VEER SINGH JATAV

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001893 PATIENT ID

: VEERM211065251 CLIENT PATIENT ID: 012310210052

ABHA NO

AGE/SEX :58 Years Male DRAWN :21/10/2023 13:02:00

RECEIVED: 21/10/2023 13:17:58 REPORTED :05/11/2023 15:20:38

Test Report Status Final Results Biological Reference Interval Units

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

ELVER FONCTION PROFILE, SEROM-45>Bilirubin</>
55>Bilirubin</>
55>Bilirubin</>
65>Bilirubin</>
65>Bilirubin</
65>Bilirubin</
65>Bevated levels</br>
may give yellow discoloration in jaundice.</br>
may give yellow discoloration in jaundice.</br>
may give yellow discoloration in jaundice.</br>
may give yellow discoloration and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

<a href="mailto:soteom

Sb>GGT</l>
 is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.
 Sb>Total Protein
 Sb>Total Protein
 Salso known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease,
 Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy, etc.
 Ab>Albumin
 Sb the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodifilation, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.
 BLOOD LIBEA NITROGEN (BLIN). SERILMA-SPALINES of Increased syndrome, protein diet. Increased protein catabolism. GL haemorrhage.

enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc
BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage,
Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr. Akansha Jain **Consultant Pathologist**



Page 11 Of 18







PATIENT NAME: VEER SINGH JATAV

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001893
PATIENT ID: VEERM211065251

CLIENT PATIENT ID: 012310210052 ABHA NO : AGE/SEX : 58 Years Male
DRAWN :21/10/2023 13:02:00
RECEIVED :21/10/2023 13:17:58
REPORTED :05/11/2023 15:20:38

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD: GROSS EXAMINATION

APPEARANCE CLEAR

METHOD: GROSS EXAMINATION

CHEMICAL EXAMINATION, URINE

METHOD: DOUBLE INDICATOR PRINCIPLE

PH 5.5 4.7 - 7.5

SPECIFIC GRAVITY <=1.005 1.003 - 1.035

METHOD: IONIC CONCENTRATION METHOD

PROTEIN NOT DETECTED NEGATIVE METHOD: PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

GLUCOSE DETECTED (+) NOT DETECTED

METHOD: GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

KETONES NOT DETECTED NOT DETECTED

METHOD: SODIUM NITROPRUSSIDE REACTION

BLOOD NOT DETECTED NEGATIVE

METHOD: PEROCIDASE ANTI PEROXIDASE
BILIRUBIN

NOT DETECTED

NOT DETECTED

METHOD : DIPSTICK

UROBILINOGEN NORMAL NORMAL

METHOD: EHRLICH REACTION REFLECTANCE

NITRITE NOT DETECTED NOT DETECTED

METHOD: NITRATE TO NITRITE CONVERSION METHOD

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) 0-1 0-5 /HPF

METHOD: DIPSTICK, MICROSCOPY

Dr. Akansha Jain Consultant Pathologist





Page 12 Of 18



View Report







AGE/SEX

PATIENT NAME: VEER SINGH JATAV REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001893 PATIENT ID : VEERM211065251

CLIENT PATIENT ID: 012310210052 ABHA NO

DRAWN :21/10/2023 13:02:00 RECEIVED: 21/10/2023 13:17:58 REPORTED :05/11/2023 15:20:38

Male

:58 Years

Test Report Status <u>Final</u>	Results	Biological Reference Inte	erval Units
EPITHELIAL CELLS METHOD: MICROSCOPIC EXAMINATION	1-2	0-5	/HPF
CASTS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION CRYSTALS METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION YEAST	NOT DETECTED	NOT DETECTED	

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
·	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary
	tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by
	genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or
	bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,
	interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal
	diseases

Dr. Akansha Jain **Consultant Pathologist**



Page 13 Of 18







PATIENT NAME: VEER SINGH JATAV REF. DOCTOR: SELF

ABHA NO

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: **0251WJ001893**PATIENT ID: VEERM211065251

CLIENT PATIENT ID: 012310210052

AGE/SEX :58 Years Male
DRAWN :21/10/2023 13:02:00
RECEIVED :21/10/2023 13:17:58
REPORTED :05/11/2023 15:20:38

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Akansha Jain Consultant Pathologist



Page 14 Of 18

View Details









CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

PATIENT NAME: VEER SINGH JATAV

WEST DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : **0251WJ001893**PATIENT ID : VEERM211065251

CLIENT PATIENT ID: 012310210052

ABHA NO :

AGE/SEX :58 Years Male DRAWN :21/10/2023 13:02:00 RECEIVED :21/10/2023 13:17:58

REPORTED :05/11/2023 15:20:38

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, STOOL

COLOUR BROWN

CONSISTENCY WELL FORMED

MUCUS NOT DETECTED NOT DETECTED
VISIBLE BLOOD ABSENT ABSENT

MICROSCOPIC EXAMINATION, STOOL

CYSTS NOT DETECTED NOT DETECTED

OVA NOT DETECTED

LARVAE NOT DETECTED NOT DETECTED
TROPHOZOITES NOT DETECTED NOT DETECTED

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as
	ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects
	presence of parasitic infestation of gastrointestinal tract. Various forms of
	parasite that can be detected include cyst, trophozoite and larvae. One negative
	result does not rule out the possibility of parasitic infestation. Intermittent
	shedding of parasites warrants examinations of multiple specimens tested on
	consecutive days. Stool specimens for parasitic examination should be collected
	before initiation of antidiarrheal therapy or antiparasitic therapy. This test does
	not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia
	and Isospora species. Examination of Ova and Parasite has been carried out by
	direct and concentration techniques.

Dr. Abhishek Sharma Consultant Microbiologist Page 15 Of 18





View Details

View Report







PATIENT NAME: VEER SINGH JATAV REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030**

8800465156

ACCESSION NO: 0251WJ001893 PATIENT ID : VEERM211065251

CLIENT PATIENT ID: 012310210052

ABHA NO

AGE/SEX :58 Years Male DRAWN :21/10/2023 13:02:00 RECEIVED: 21/10/2023 13:17:58

REPORTED :05/11/2023 15:20:38

Test Report Status Final Results Biological Reference Interval Units

Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

ADDITIONAL STOOL TESTS:

- Stool Culture:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if 1. treatment for GI infection worked.
- 2. Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
- 3. Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- 4. Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- 5. Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- 6. Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Dr. Abhishek Sharma **Consultant Microbiologist** Page 16 Of 18













PATIENT NAME: VEER SINGH JATAV REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001893 PATIENT ID : VEERM211065251

CLIENT PATIENT ID: 012310210052 ABHA NO

DRAWN

AGE/SEX

:21/10/2023 13:02:00 RECEIVED: 21/10/2023 13:17:58

Male

REPORTED :05/11/2023 15:20:38

:58 Years

Test Report Status Final Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

THYROID PANEL, SERUM

73	101.13	60.0 - 181.0	ng/dL
METHOD: CHEMILUMINESCENCE			
T4	10.10	4.5 - 10.9	μg/dL
METHOD: CHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	3.259	0.550 - 4.780	$\mu IU/mL$
METHOD: CHEMILUMINESCENCE			

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3 Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Dr. Akansha Jain **Consultant Pathologist**



Page 17 Of 18









CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

PATIENT NAME: VEER SINGH JATAV

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO : **0251WJ001893**PATIENT ID : VEERM211065251

CLIENT PATIENT ID: 012310210052 ABHA NO : AGE/SEX :58 Years Male DRAWN :21/10/2023 13:02:00 RECEIVED :21/10/2023 13:17:58

REPORTED :05/11/2023 15:20:38

Test Report Status <u>Final</u> Results Biological Reference Interval Units

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession







Page 18 Of 18

View Details

View Report

